Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy

Abstract Background In situ tumor vaccine has been gradually becoming a hot research field for its advantage of achieving personalized tumor therapy without prior antigen identification. Various in situ tumor vaccine regimens have been reported to exert considerable antitumor efficacy in preclinical...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Journal of Translational Medicine
المؤلفون الرئيسيون: Zhichen Sun, Yanhong Chu, Jie Xiao, Yueling Yang, Fanyan Meng, Xinyue Wang, Yanbing Dong, Junmeng Zhu, Yirong Wu, Lanqun Qin, Yaohua Ke, Baorui Liu, Qin Liu
التنسيق: مقال
اللغة:الإنجليزية
منشور في: BMC 2023-09-01
الموضوعات:
TLR9 agonist
OX40 agonist
Radiation
In situ vaccine
Tumor microenvironment
الوصول للمادة أونلاين:https://doi.org/10.1186/s12967-023-04504-w

الانترنت

https://doi.org/10.1186/s12967-023-04504-w

مواد مشابهة